Kivisäkk, Pia http://orcid.org/0000-0001-9708-7509
Fatima, Hadia A.
Cahoon, Danielle S.
Otieno, Brunah
Chacko, Leena
Minooei, Farnaz
Demos, Catherine
Stengelin, Martin
Sigal, George
Wohlstadter, Jacob
Arnold, Steven E.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (P30AG062421)
Challenger Foundation
Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer’s disease
Article History
Received: 7 September 2023
Accepted: 31 December 2023
First Online: 5 January 2024
Competing interests
: P.K., S.E.A., and M.S. are named as co-inventors on a US patent application related to neurological biomarker assays that is jointly held by Massachusetts General Hospital and Meso Scale Technologies, LLC., an affiliate of Meso Scale Diagnostics, LLC. (<i>dba</i> Meso Scale Discovery). S.E.A. has received advisory board or consulting fees from Allyx Therapeutics, Bob's Last Marathon, Boyle Shaughnessy Law, Daewoong Pharmaceutical Co., Eisai, Jocasta Neuroscience, Quince Therapeutics (formerly Cortexyme), Risen Pharmaceutical Technology, and Sage Therapeutics. B.O., L.C., F.M., C.D., M.S., and G.S. are paid employees and J.W. is an officer of Meso Scale Diagnostics, LLC. H.A.F. and D.S.C. have no declarations of interest.